“…The use of medetomidine, a short acting α 2 ‐AR agonist with the highest selectivity to the α 2 ‐AR (1620:1 vs. 160:1 for xylazine; Virtanen et al ., ; Scheinin et al ., ), has been described in horses (Yamashita et al ., ; Grimsrud et al ., ). Medetomidine has been reported to produce good sedation (Bryant et al ., ; Hobo et al ., ) and decrease mechanical nociception (Grimsrud et al ., ) but seems to cause a greater degree of ataxia when compared to xylazine in horses (Bryant et al ., ). The cardiovascular effects of medetomidine are dose‐dependent and similar to the effects observed with detomidine, but of shorter duration (Yamashita et al ., ).…”